Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 8INDUSTRY 4NETWORK 1INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 4Breast Neoplasms 4Sarcoma 3Rhabdomyosarcoma 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma 2Teratoma 1Sarcoma, Synovial 1Recurrent Uterine Corpus Sarcoma 1Recurrent Uterine Corpus Carcinoma 1Pancreatic Neoplasms 1Neutropenia 1Neurofibrosarcoma 1Malignant mesenchymal tumor 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Follicular 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Leiomyosarcoma 1Kidney Neoplasms 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Carboplatin 34Paclitaxel 29Radiotherapy 23Cisplatin 23Docetaxel 18Pemetrexed 14Gemcitabine 14Radiosurgery 10Bevacizumab 9Magnetic Resonance Spectroscopy 7Etoposide 7Ramucirumab 6Erlotinib Hydrochloride 6Cetuximab 6Specimen Handling 5Gene Expression Profiling 5durvalumab 4cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Amplified Fragment Length Polymorphism Analysis 4pembrolizumab 3cemiplimab 3Watchful Waiting 3Taxes 3Surgical Procedures, Operative 3Radiotherapy, Conformal 3Psychiatric Rehabilitation 3Neoadjuvant Therapy 3Fluorodeoxyglucose F18 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Non-Small-Cell Lung × pegfilgrastim × Clear all
NCT00113386 2013-06-28

Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer

Radiation Therapy Oncology Group

Phase 3 Terminated
19 enrolled 5 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡